Aims: HtrA1 is a member of the HtrA (high-temperature requirement factor A) family of serine proteases. HtrA1 plays a protective role in various malignancies due to its tumour suppressive properties. The aim of this study was to determine HtrA1 expression as a predictor of chemoresponse in patients with advanced gastric cancer. Methods and results: HtrA1 expression was determined by immunohistochemistry on specimens of primary gastric cancer from 80 patients treated consecutively with cisplatin-based combination chemotherapy. Response to chemotherapy was assessed according to Response Evaluation Criteria in Solid Tumours (RECIST) criteria. Our population consisted of males/females [51/29; median age 64 years (range 32-82)]. A complete or partial response was observed in 71.4% [95% confidence interval (CI) 54.7-88.2], 66.7% (95% CI 47.8-85.5) and 28.6% (95 CI 11.8-45.3) of tumours showing high, medium and low HtrA1 expression, respectively. A statistically significant association between HtrA1 expression and the clinical response was observed (P = 0.002). The median overall survival for patients with high/medium expression was 17 months compared to 9.5 months for patients with low HtrA1 expression (P = 0.037). Conclusions: Identification of HtrA1 in gastric cancer prior to chemotherapy indicates that levels of HtrA1 could be used to predict response to platinum-based combination therapies. Further assessment of HtrA1 expression is highly warranted in large, prospective studies.

HtrA1, a potential predictor of response to cisplatin-based combination chemotherapy in gastric cancer / Vincenzo, Catalano; Pasquale, Mellone; Alfredo, D'Avino; Viji, Shridhar; Maria Pia, Staccioli; Francesco, Graziano; Paolo, Giordani; David, Rossi; Anna Maria, Baldelli; Paolo, Alessandroni; Daniele, Santini; Lorenzon, Laura; Enrica, Testa; Silvia, D'Emidio; Michele De, Nictolis; Pietro, Muretto; Stefano Luzi, Fedeli; Alfonso, Baldi; Santini, Daniele. - In: HISTOPATHOLOGY. - ISSN 0309-0167. - 58:5(2011), pp. 669-678. [10.1111/j.1365-2559.2011.03818.x]

HtrA1, a potential predictor of response to cisplatin-based combination chemotherapy in gastric cancer

LORENZON, LAURA;SANTINI, DANIELE
2011

Abstract

Aims: HtrA1 is a member of the HtrA (high-temperature requirement factor A) family of serine proteases. HtrA1 plays a protective role in various malignancies due to its tumour suppressive properties. The aim of this study was to determine HtrA1 expression as a predictor of chemoresponse in patients with advanced gastric cancer. Methods and results: HtrA1 expression was determined by immunohistochemistry on specimens of primary gastric cancer from 80 patients treated consecutively with cisplatin-based combination chemotherapy. Response to chemotherapy was assessed according to Response Evaluation Criteria in Solid Tumours (RECIST) criteria. Our population consisted of males/females [51/29; median age 64 years (range 32-82)]. A complete or partial response was observed in 71.4% [95% confidence interval (CI) 54.7-88.2], 66.7% (95% CI 47.8-85.5) and 28.6% (95 CI 11.8-45.3) of tumours showing high, medium and low HtrA1 expression, respectively. A statistically significant association between HtrA1 expression and the clinical response was observed (P = 0.002). The median overall survival for patients with high/medium expression was 17 months compared to 9.5 months for patients with low HtrA1 expression (P = 0.037). Conclusions: Identification of HtrA1 in gastric cancer prior to chemotherapy indicates that levels of HtrA1 could be used to predict response to platinum-based combination therapies. Further assessment of HtrA1 expression is highly warranted in large, prospective studies.
2011
chemoresistance; chemotherapy; cisplatin; gastric cancer; htra1
01 Pubblicazione su rivista::01a Articolo in rivista
HtrA1, a potential predictor of response to cisplatin-based combination chemotherapy in gastric cancer / Vincenzo, Catalano; Pasquale, Mellone; Alfredo, D'Avino; Viji, Shridhar; Maria Pia, Staccioli; Francesco, Graziano; Paolo, Giordani; David, Rossi; Anna Maria, Baldelli; Paolo, Alessandroni; Daniele, Santini; Lorenzon, Laura; Enrica, Testa; Silvia, D'Emidio; Michele De, Nictolis; Pietro, Muretto; Stefano Luzi, Fedeli; Alfonso, Baldi; Santini, Daniele. - In: HISTOPATHOLOGY. - ISSN 0309-0167. - 58:5(2011), pp. 669-678. [10.1111/j.1365-2559.2011.03818.x]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/382784
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 20
social impact